Biohaven enrolls first patient in phase 2/3 trial of oral zavegepant, prompting $100 million milestone funding payment from royalty pharma

New haven, conn., march 29, 2021 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking